Articles On Amplia Therapeutics (ASX:ATX)

Markets pricing a 78pc chance of rate cut following labour data Unemployment levels remained steady ASX dips on broad weakness in tech, resources and healthcare stocks   The ASX ended up in negative territory this afternoon, but not by mu...

The ASX 200 traded flat today, as the index keeps tracking sideways for a fourth straight day. Financials, Real Estate, and Discretionary were substantially in the green, while on the other side Materials, Utilities, and IT stocks were s...

Highlights Amplia Therapeutics surges on clinical update in pancreatic cancer trial ASX 200 dampened by declines in tech, energy, and materials sectors Bank stocks and selective healthcare names provide morning stability...

Amplia Therapeutics (ASX:ATX) has been the most watched on HotCopper forums through today after huge results from its ACCENT trials set up to look into how its FAK inhibitor, Narmafotinib, combats cancer. Listen to the HotCopper podcast...

Orthocell says its Remplir nerve device blitzes the stitches Singular Health inks US physician network deal Clarity clearly is undervalued, say brokers   Among other auspicious events, the 19th of June marks the end of slavery in the US,...

Amplia Therapeutics (ASX: ATX) continues to make excellent progress with focal adhesion kinase (FAK) inhibitor narmafotinib, its best-in-class drug candidate for pancreatic cancer. New data from the company’s ongoing ACCENT trial investigat...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

Highlights Santos (ASX:STO) gains after external proposal confirmed due diligence process Uranium stocks including Boss Energy (ASX:BOE) and Paladin Energy (ASX:PDN) trade higher Energy sector leads early trade on ASX 200...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin HIGHLIGHTS A confirmed pathological complete response has been recorded in the ACCE...

Highlights Energy sector stocks lift the All Ordinaries and ASX 200 in early trade Santos (ASX:STO) receives takeover proposal from overseas consortium Uranium explorers including Deep Yellow (ASX:DYL) and Boss Energy (ASX:B...

Highlights Energy stocks strengthen ASX with significant upward movement Uranium and iron ore companies display broad early momentum Clinical and tech sector updates drive Amplia and archTIS gains  Energy stock...

Highlights Energy sector lifts the ASX 200 in early trading Uranium and oil stocks show strong momentum Activity surges across key players including Santos, Deep Yellow, and Boss Energy The energy segme...

4DS Memory (ASX:4DS) has been the most watched stock on HotCopper forums so far today, on news that its Sixth Platform Lot results did not quite meet expectations. 4DS Memory has been down 58% at 2.6 cents. Listen to the HotCopper podcas...

Amplia Therapeutics (ASX: ATX) has recorded the first pathological complete response (pCR) from a patient participating in the company’s ongoing ACCENT clinical trial to treat metastatic pancreatic cancer. The trial is investigating the com...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

Highlights  ASX 200 set to rise as confidence surveys and interest rate expectations drive sentiment  Strong sectoral gains led by Financials and Energy boost broader market optimism  Small-cap momentum supported by updates from compa...

Despite a strong start, the ASX has paired back gains to finish down 2.9 points or 0.03pc Weakness came from the Health Care sector and gold stocks Info Tech sector rides semiconductor fever higher, up 0.71pc Despite a strong start to the...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Highlights ASX 200 futures signal a stronger open amid renewed global optimism US indices rally as tariff tensions ease and consumer sentiment improves Key ASX companies including ASX:GMG, ASX:WEB, ASX:FPH, ASX:IFT and ASX:M...

With some common types of cancers including breast and lung, therapies have developed at a rapid clip. The same can’t be said for pancreatic cancer, which is not among the most common tumours but ranks number one as the deadliest. Only 12%...

US government debt was downgraded from AAA to AA1 Iron ore falls as data out of China shows weakening growth Gold climbs 0.62pc to US$3223/oz   After eight days of gains the ASX has finally stumbled, ending the day down 0.58%. It’s unlike...

Highlights GreenPeak Rare Earths (PEK) rose sharply following acquisition news Brightstar Resources (BTR) advanced with second processing campaign launch Treasury Wine Estates (TWE) declined after leadership change announcem...

Highlights: ASX 200 rebounds after early decline, supported by gains in financials and technology sectors Xero (ASX:XRO) jumps after strong revenue and profit growth despite net profit after tax miss Insurance Australia Grou...

Highlights Amplia Therapeutics (ASX:ATX) surges following positive pancreatic cancer trial update LI-S Energy (ASX:LIS) gains with progress on drone battery platform and lithium foil project ASX 200 opens lower amid broad se...

ASX posts 0.22pc gains, recovering from dip earlier in the day Xero brings big profit and revenue gains in quarterly report, lifting stock 4.7pc Insurance Australia surges 5.7pc on Royal Automobile Club of Western Australia deal   It was...

The ASX200 closed up 0.22% at 8,297 points. IT was the best performing sector, up 2.0%, followed by Financials, up 1.1%, and Discretionary, up 1%. Real Estate was the worst performing sector, down 1.3%, followed by Energy, down 1.1%,...

Amplia Therapeutics (ASX:ATX) has popped over +40% in lunchtime trades as the company reports its products provide superior outcomes when coupled with chemotherapy, at least in one ‘ACCENT’ trial announced on Thursday. “The ACCENT trial...

Amplia says it has reached the requisite level of ‘partial responders’ in its mid-stage pancreatic cancer study Immutep reports “remarkable” response rates in a German-based lung cancer trial Paradigm wins US ethics approval for knee osteo...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10:15, once trading kicks off in earnes...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

By stockpiling components, the US-focused Impedimed is taking no chances with tariffs Cashed-up Amplia forges ahead with promising pancreatic cancer trial Some biotechs are headed to the well, while others are rolling in the green stuff...

AdAlta subsidiary AdCella brings cutting-edge cellular immunotherapies from Asia – particularly China – into Western markets AdCella has backing of SYNthesis BioVentures Fund, which invests in therapeutics development The biotech fund beli...

Highlights Insiders purchased AU$949.9k in ATX stock last year. Current value now stands at AU$714.9k following a 21% decline. Insider ownership is 15% of the company. Over the last year, insiders at Amplia Therapeutics Limited (A...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

Highlights Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options. AdAlta, Cynata, and Amplia are advancing innovative therapeutic approaches. Australian biotechnology companies are expanding...

Idiopathic pulmonary fibrosis is a life-threatening lung disease AdAlta’s lead candidate AD-214 is a first-in-class molecule designed to treat IPF Amplia and Cynata therapies also show promise in treating the disease, which has limited tre...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

A number of ASX-listed healthcare companies, many with relatively low market caps, are making strides in tackling cancer Imagion is  aiming to revolutionise cancer diagnosis by introducing molecular imaging to magnetic resonance imaging (M...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

Syntara aims for FDA ‘breakthrough’ therapy status for its myelofibrosis drug candidate FAK! More promising results from Amplia’s pancreatic cancer trial Oh, you shouldn’t have! Broker Morgans’ Christmas biotech hamper   Armed with encour...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

  ASX slumps heavily after inflation data Australian inflation drops to 2.8pc, lower than expected Mining stocks rise while supermarket stocks struggle   The ASX trimmed its earlier gains following better-than-expected inflation figures....

Nyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharmaceuticals ‘mini me’ Percheron seeks funds for rare disease program Another win for Pro Medicus, this time locally   Nyrada (ASX:NYR) share...

Amplia CEO Dr Chris Burns and long-time scientific collaborator Professor Andrew Wilks have been awarded the 2024 Prime Minister’s Prize for Innovation The scientists were recognised for their breakthrough in developing momelotinib, a drug...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Thursday, September 24, 2024—a significant date in the annals of Wall Street. This day marks the anniversary of a notorious event in financial history: the failed attempt to corner the U.S. gold market, which resulted in economic upheaval a...

  ASX dips amid concerns over delayed RBA rate cuts Woolworths and Coles hit with lawsuit over misleading discounts Gold miners and uranium stocks gain   The ASX took a breather from its record highs, down by 0.6% after being rattled by...

  Amplia Therapeutics (ASX:ATX) announced that its Phase 2a clinical trial, known as the ACCENT trial, is continuing enrolment for narmafotinib in the treatment of advanced pancreatic cancer. Six out of 16 patients assessed have shown confi...